Tay-Sachs Disease: A Concise Overview of This Genetic Disorder

Tay-Sachs disease (TSD) is a rare, fatal autosomal recessive neurodegenerative disorder caused by deficiency of β-hexosaminidase A (HexA), leading to GM2 ganglioside accumulation in neurons.

Key Facts

  • Gene: HEXA (15q23-q24); >200 pathogenic variants.
  • Inheritance: Autosomal recessive; carrier frequency ~1/30 Ashkenazi Jewish, 1/250 general.
  • Forms: Classic infantile (onset 3–6 mo, death by 4–5), Juvenile (2–10 yr), Late-onset (adolescence+).
  • Hallmark: Cherry-red spot on macula (infantile).
  • Symptoms: Developmental regression, hypotonia→spasticity, seizures, blindness, dysphagia.
  • Diagnosis: HexA enzyme assay (leukocytes) + HEXA sequencing.
  • Treatment: Supportive only (seizure control, nutrition, respiratory, palliative). No disease-modifying therapy yet.
  • Research: Gene therapy (AAV-HEXA), substrate reduction, pharmacological chaperones, enzyme replacement.
  • Prevention: Carrier screening (enzyme + DNA), prenatal diagnosis, PGT-M.

Historical Note

Named for Warren Tay (1881, cherry-red spot) and Bernard Sachs (1887, cellular pathology + Ashkenazi predilection). Not related to any famous affected individuals — it is uniformly fatal in infancy without exception in classic form.

TSD exemplifies the power of carrier screening to prevent a devastating genetic disease.

Eating Disorders - Related Articles